Business Context and Reporting Period
This Form 8-K is a current report filed by Athira Pharma, Inc. (not Leonabio, Inc.) on March 8, 2021, covering events occurring on March 4, 2021. The company is a Delaware corporation listed on the Nasdaq Global Select Market under the symbol ATHA and is classified as an Emerging Growth Company.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material change reported is the appointment of a new director to the Board of Directors:
- Appointment: Barbara Kosacz was appointed as a Class I director, effective March 4, 2021.
- Committee Role: Ms. Kosacz was appointed to the Nominating and Corporate Governance Committee.
- Term: Her term expires at the 2021 annual meeting of stockholders.
- Compensation: She will participate in the standard compensation plan for non-employee directors, including an initial stock option grant effective March 4, 2021.
- Related Party Transactions: The filing states there are no transactions or proposed transactions between Ms. Kosacz (or her immediate family) and the Company.
Guidance, Outlook, and Risks
This filing does not provide financial guidance, outlook, management commentary on operations, or specific risk factors. It strictly addresses the corporate governance event described above.
Investor Verification Checklist
- Verify the correct registrant name is Athira Pharma, Inc. (ATHA), not Leonabio, Inc.
- Confirm the effective date of Barbara Kosacz's directorship is March 4, 2021.
- Review the standard compensation plan for non-employee directors referenced in the Form S-1 (File No. 333-248428) to understand the terms of the stock option grant.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.